Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063141 · ClinicalTrials.gov registry record · Phase 3
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,302
- Enrollment target
NCT00063141 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,302 participants.
The verdict
NCT00063141, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,302 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.
Interventions
- DRUG cetuximab
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,302 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063141
The ClinicalTrials.gov registry entry for NCT00063141 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cetuximab is the first listed.
NCT00063141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063141 about?
NCT00063141 is a clinical study titled "Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer". The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatm...
What is the current status of trial NCT00063141?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,302 participants. The study started on 2003-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00063141?
The interventions under investigation include: cetuximab (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00063141?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.